Conference Presentation

Enterome's EO2463 vaccine posts 74% ORR in lymphoma combination cohort

Updated SIDNEY data due at the Pan Pacific Lymphoma Conference will test whether an off-the-shelf peptide vaccine can hold its interim response and durability numbers as more patients mature.

By AppliedXLJuly 14, 2026Trial NCT04669171

Executive Summary

Enterome has already disclosed interim response and durability data for its EO2463 lymphoma vaccine, and the upcoming conference presentation extends that same dataset rather than introducing a first readout.
The combination-therapy cohort produced response and complete-response rates well above what watchful waiting alone would be expected to show, in a population that otherwise receives no active treatment.
The trial is not designed as a registrational study, and its primary completion date has been pushed out repeatedly, most recently by years rather than months, so the near-term signal does not by itself set a regulatory timeline.
No other program in this indication shares the vaccine's target class or modality, leaving EO2463 without a direct precedent to benchmark its response rates against.

The update

Enterome is scheduled to present updated data from the ongoing SIDNEY study (NCT04669171) at the Pan Pacific Lymphoma Conference in Hawaii on July 20, 2026. The presentation follows two rounds of interim disclosures earlier this year: a May 28 press release reporting a 52.6% objective response rate in 19 evaluable follicular lymphoma patients treated with EO2463 monotherapy in the watch-and-wait setting, and a June 15 update at the European Hematology Association congress reporting a 41% ORR in that same monotherapy cohort alongside a 74% ORR and 61% complete response rate in patients receiving EO2463 combined with lenalidomide and rituximab. The July presentation is expected to extend, not originate, this dataset. NCT04669171+1

What the trial tests

SIDNEY is a multi-cohort Phase 1/2 study of EO2463, an off-the-shelf peptide vaccine designed to expand CD8 T-cells that cross-react with B-cell lymphoma markers. The study enrolls previously untreated, low-tumor-burden patients suitable for watchful waiting as monotherapy, and relapsed or refractory patients in combination with rituximab or with lenalidomide plus rituximab. Across the disclosed cohorts, positive immune responses were confirmed in 43 of 48 tested patients, and the June data reported a median duration of objective response of 35.2 months in the combination cohort, with EO2463-induced T-cell expansion statistically associated with objective response on monotherapy and with complete response on the combination regimen. The company has stated it is seeking partners and investors to advance registrational development. Enterome

The stake

"Patients in the watch-and-wait setting currently receive no active treatment despite the psychological burden of their diagnosis," Enterome Chief Executive Officer Pierre Belichard said, adding the company believes EO2463 could change that paradigm. No approved or late-stage therapy targets that watch-and-wait population directly, and no competing program in this indication shares EO2463's target class or its vaccine modality. The nearest active trials in the indication use bispecific antibodies, CAR-T therapies, or monoclonal antibodies against CD19 or CD20, including Genmab's epcoritamab and Gilead's axicabtagene ciloleucel, none of which shares EO2463's peptide-vaccine mechanism. Given that isolation, a result that shows durable responses persisting as more patients mature, without a drop back toward the level expected from watchful waiting alone, is what would distinguish this update. Enterome

Timeline and operational read

The trial's primary completion date has moved three times since 2024, from September 2024 to June 2025, then to May 2026, and most recently in January 2026 to May 2029, alongside an enrollment target increase from 60 to 80 patients. The trial remains in Recruiting status, and the enrollment increase alongside the later completion date reflects an expanding, still-enrolling study rather than a program in distress. The FDA granted EO2463 Fast Track designation for follicular lymphoma in the watch-and-wait setting in October 2025 and Orphan Drug Designation in May 2026, designations that signal an unmet-need setting rather than a predictor of eventual approval. NCT04669171+1

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.